Ascendis Pharma A (ASND) Intangibles (2020 - 2026)
Ascendis Pharma A (ASND) posted Intangibles of $4.3 million for Q1 2026, little changed sequentially from $4.3 million in Q4 2025, and up 5.04% YoY from $4.1 million in Q1 2025.
Ascendis Pharma A (ASND) Intangibles (2020 - 2026) Analysis & Trends
Ascendis Pharma A has reported Intangibles for 7 years, with the latest figure at $4.3 million in Q1 2026.
- Quarterly Intangibles rose 5.04% year-over-year to $4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.3 million (up 5.04% YoY) and the FY2025 annual result came in at $4.3 million, changed 0.33% from the prior year.
- Intangibles was little changed at $4.3 million in Q1 2026 per ASND's latest filing, from $4.3 million in the prior quarter.
- Over five years, Intangibles peaked at $6.2 million in Q4 2023 and troughed at $4.1 million in Q1 2025.
- A 5-year average of $4.7 million and a median of $4.4 million in 2025 frame the typical range for Intangibles.
- The sharpest annual moves came in 2023 and 2024: Intangibles rose 6.82% in 2023, then plunged 30.92% in 2024.
- Over 5 years, Intangibles stood at $5.8 million in 2022, then gained by 6.82% to $6.2 million in 2023, then plunged by 30.92% to $4.3 million in 2024, then grew by 0.33% to $4.3 million in 2025, then gained by 0.01% to $4.3 million in 2026.
- According to Business Quant data, Intangibles over the past three periods registered $4.3 million, $4.3 million, and $4.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | 4.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.32 Mn |
| Dec 31, 2025 | 4.32 Mn |
| Sep 30, 2025 | 4.37 Mn |
| Jun 30, 2025 | 4.29 Mn |
| Mar 31, 2025 | 4.11 Mn |
| Dec 31, 2024 | 4.30 Mn |
| Sep 30, 2024 | 4.51 Mn |
| Jun 30, 2024 | 4.51 Mn |
| Mar 31, 2024 | 4.67 Mn |
| Dec 31, 2023 | 6.23 Mn |
| Dec 31, 2022 | 5.83 Mn |
| Dec 31, 2021 | 6.54 Mn |
| Dec 31, 2020 | 6.82 Mn |